Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: BCL004
MIFTS: 38

B-Cell Non-Hodgkin Lymphoma

Categories: Blood diseases, Immune diseases, Rare diseases
Genes Variations Tissues Related diseases Publications Pathways Drugs
Sources

Aliases & Classifications for B-Cell Non-Hodgkin Lymphoma

About this section

MalaCards integrated aliases for B-Cell Non-Hodgkin Lymphoma:

Name: B-Cell Non-Hodgkin Lymphoma 59 29 6
B-Cell Non-Hodgkins Lymphoma 17
B-Cell Nhl 59

Classifications:

MalaCards categories:
Global: Rare diseases
Anatomical: Blood diseases Immune diseases
See all MalaCards categories (disease lists)
Orphanet: 59  
Rare haematological diseases


External Ids:

Orphanet 59 ORPHA171915
Sources

Summaries for B-Cell Non-Hodgkin Lymphoma

About this section
MalaCards based summary : B-Cell Non-Hodgkin Lymphoma, also known as b-cell non-hodgkins lymphoma, is related to lymphoma, non-hodgkin, familial and lymphoma. An important gene associated with B-Cell Non-Hodgkin Lymphoma is BCL6 (BCL6 Transcription Repressor), and among its related pathways/superpathways are NF-kappaB Signaling and B Cell Development Pathways. The drugs Ketamine and Pixantrone have been mentioned in the context of this disorder. Affiliated tissues include b cells, t cells and bone.

Sources

Related Diseases for B-Cell Non-Hodgkin Lymphoma

About this section

Diseases in the B-Cell Non-Hodgkin Lymphoma family:

T-Cell Non-Hodgkin Lymphoma

Diseases related to B-Cell Non-Hodgkin Lymphoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 179)
# Related Disease Score Top Affiliating Genes
1 lymphoma, non-hodgkin, familial 31.2 MS4A1 BCL6 ATM
2 lymphoma 31.1 NFKB2 BCL7A BCL6 ATM
3 burkitt lymphoma 30.5 MS4A1 BCL7A BCL6
4 leukemia, chronic lymphocytic 29.9 MS4A1 BCL6 ATM
5 plasmablastic lymphoma 29.8 MS4A1 BCL6
6 aggressive b-cell non-hodgkin lymphoma 12.9
7 indolent b-cell non-hodgkin lymphoma 12.9
8 mantle cell lymphoma 12.0
9 lymphoma, hodgkin, classic 11.4
10 b-cell lymphoma 11.2
11 diffuse large b-cell lymphoma 11.1
12 follicular lymphoma 11.0
13 neutropenia 11.0
14 lymphocytic leukemia 10.9
15 leukemia, b-cell, chronic 10.8
16 marginal zone b-cell lymphoma 10.8
17 hepatitis c virus 10.6
18 hepatitis c 10.6
19 hematopoietic stem cell transplantation 10.6
20 leukemia, acute lymphoblastic 10.5
21 myeloma, multiple 10.5
22 lymphoplasmacytic lymphoma 10.5
23 thrombocytopenia 10.5
24 cryoglobulinemia 10.5
25 cll/sll 10.5
26 autoimmune disease 10.5
27 cryoglobulinemia, familial mixed 10.5
28 myelodysplastic syndrome 10.5
29 lymphopenia 10.5
30 splenic marginal zone lymphoma 10.4
31 primary mediastinal b-cell lymphoma 10.4
32 hairy cell leukemia 10.4
33 severe combined immunodeficiency 10.4
34 lymphosarcoma 10.4
35 splenomegaly 10.4
36 lymphoma, mucosa-associated lymphoid type 10.3
37 leukemia, acute lymphoblastic 3 10.3
38 nodal marginal zone lymphoma 10.3
39 agammaglobulinemia 10.3
40 peripheral nervous system disease 10.3
41 vasculitis 10.3
42 neuropathy 10.3
43 indolent b cell lymphoma 10.3
44 multinucleated neurons, anhydramnios, renal dysplasia, cerebellar hypoplasia, and hydranencephaly 10.3
45 leukemia, acute myeloid 10.3
46 exanthem 10.3
47 paroxysmal nocturnal hemoglobinuria 10.3
48 lymphoproliferative syndrome 10.3
49 lymphoblastic lymphoma 10.3
50 common variable immunodeficiency 10.3

Graphical network of the top 20 diseases related to B-Cell Non-Hodgkin Lymphoma:



Diseases related to B-Cell Non-Hodgkin Lymphoma
Sources

Symptoms & Phenotypes for B-Cell Non-Hodgkin Lymphoma

About this section
Sources

Drugs & Therapeutics for B-Cell Non-Hodgkin Lymphoma

About this section

Drugs for B-Cell Non-Hodgkin Lymphoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 264)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ketamine Approved, Vet_approved Phase 3 6740-88-1 3821
2
Pixantrone Approved, Investigational Phase 3 144510-96-3
3
Sargramostim Approved, Investigational Phase 3 83869-56-1, 123774-72-1
4
Cisplatin Approved Phase 3 15663-27-1 84093 441203 2767
5
Allopurinol Approved Phase 3 315-30-0 2094
6
Bleomycin Approved, Investigational Phase 3 11056-06-7 5360373
7
Lenalidomide Approved Phase 3 191732-72-6 216326
8
Lenograstim Approved, Investigational Phase 2, Phase 3 135968-09-1
9
Prednisolone phosphate Approved, Vet_approved Phase 3 302-25-0
10
Methylprednisolone Approved, Vet_approved Phase 3 83-43-2 6741
11
Methylprednisolone hemisuccinate Approved Phase 3 2921-57-5
12
Prednisolone Approved, Vet_approved Phase 3 50-24-8 5755
13
Vindesine Approved, Investigational Phase 3 59917-39-4, 53643-48-4 40839
14
Levoleucovorin Approved, Investigational Phase 2, Phase 3 68538-85-2
15
Idarubicin Approved Phase 3 58957-92-9 42890
16
Rasburicase Approved, Investigational Phase 2, Phase 3 134774-45-1
17
ofatumumab Approved Phase 3 679818-59-8 6918251
18
Cytarabine Approved, Experimental, Investigational Phase 3 147-94-4, 65-46-3 6253
19
Etoposide Approved Phase 3 33419-42-0 36462
20
Carmustine Approved, Investigational Phase 3 154-93-8 2578
21
Melphalan Approved Phase 3 148-82-3 460612 4053
22
Calcium Approved, Nutraceutical Phase 3 7440-70-2 271
23
Ginseng Approved, Investigational, Nutraceutical Phase 3 50647-08-0
24
Folic acid Approved, Nutraceutical, Vet_approved Phase 2, Phase 3 59-30-3 6037
25
Prednisolone hemisuccinate Experimental Phase 3 2920-86-7
26 Anesthetics, Intravenous Phase 3
27 Anesthetics, General Phase 3
28 Excitatory Amino Acid Antagonists Phase 3
29 Anesthetics, Dissociative Phase 3
30 Excitatory Amino Acids Phase 3
31 Folic Acid Antagonists Phase 3
32 Nucleic Acid Synthesis Inhibitors Phase 3
33 Calcium, Dietary Phase 3
34 Analgesics, Opioid Phase 3
35 Narcotics Phase 3
36 Free Radical Scavengers Phase 3
37 Antioxidants Phase 3
38 Angiogenesis Inhibitors Phase 3
39 Angiogenesis Modulating Agents Phase 3
40 Anti-Infective Agents Phase 2, Phase 3
41 Antimetabolites Phase 2, Phase 3
42 Antimetabolites, Antineoplastic Phase 2, Phase 3
43 Vitamin B9 Phase 2, Phase 3
44 Folate Phase 2, Phase 3
45 Vitamin B Complex Phase 2, Phase 3
46 Micronutrients Phase 2, Phase 3
47 Nutrients Phase 2, Phase 3
48 Trace Elements Phase 2, Phase 3
49 Adjuvants, Immunologic Phase 2, Phase 3
50 Prednisolone acetate Phase 3

Interventional clinical trials:

(show top 50) (show all 262)
# Name Status NCT ID Phase Drugs
1 A Randomized Double-Blind Controlled Trial of Ketamine Versus Placebo in Conjunction With Best Pain Management in Neuropathic Pain in Cancer Patients Unknown status NCT01316744 Phase 3 ketamine hydrochloride
2 Compared the Efficacy and Safety of CDOP Combined With Chidamide and CDOP in de Novo Peripheral T Cell Lymphoma Patients Unknown status NCT03023358 Phase 3 chidamide;cyclophosphamide;liposomal doxorubicin;vincristine;prednisone
3 A Randomized, Double-Blind Study Evaluating the Efficacy, Safety and Immunogenicity of ABP 798 Compared With Rituximab in Subjects With CD20 Positive B-Cell Non-Hodgkin Lymphoma (NHL) Completed NCT02747043 Phase 3 ABP 798;Rituximab
4 A Multicentre, Randomized Phase III Study of Rituximab as Maintenance Treatment Versus Observation Alone in Patients With Aggressive B-cell Lymphoma: NHL-13 Completed NCT00400478 Phase 3 Rituximab
5 A Randomized Multicenter Study Comparing Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma Who Have Relapsed After Therapy With CHOP-R or an Equivalent Regimen and Are Ineligible for Stem Cell Transplant Completed NCT01321541 Phase 3 Pixantrone + Rituximab;Gemcitabine + Rituximab
6 A Randomised Phase III Study On The Effect Of The Chimeric Anti-CD20 Monoclonal Antibody (Mabthera) During Sequential Chemotherapy Followed By Autologous Stem Cell Transplantation In Patients With Relapse B-Cell Non-Hodgkin Lymphoma(HOVON 44 STUDY) Completed NCT00012051 Phase 3 carmustine;cisplatin;cytarabine;dexamethasone;etoposide;ifosfamide;melphalan;methotrexate
7 A Phase III Randomized Trial of Low-Dose Versus Standard-Dose mBACOD Chemotherapy With rGM-CSF for Treatment of AIDS-Associated Non-Hodgkin's Lymphoma Completed NCT00000658 Phase 3 Bleomycin sulfate;Vincristine sulfate;Doxorubicin hydrochloride;Cyclophosphamide;Allopurinol;Methotrexate;Cytarabine;Leucovorin calcium;Sargramostim;Dexamethasone
8 A Phase III Multicenter, Open-label Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-cell or Follicular Non-Hodgkin's Lymphoma Completed NCT00719472 Phase 3 Rituximab;CHOP (cyclophosphamide, hydroxydaunorubicin [doxorubicin], Oncovin [vincristine], prednisone);CVP (cyclophosphamide, vincristine, prednisone);Analgesic/antipyretic and antihistamine drugs
9 Preparatory Aid to Improve Decision Making About Cancer Clinical Trials (PRE-ACT) Completed NCT00750009 Phase 3
10 The Use of American Ginseng (Panax Quinquefolius) to Improve Cancer-Related Fatigue: A Randomized, Double-Blind, Placebo-Controlled Phase III Study Completed NCT00719563 Phase 3 American ginseng
11 Phase III Randomized Trial of an Opioid Titration Order Sheet Compared to Standard of Care in Patients With Cancer Related Pain. Completed NCT00666211 Phase 3
12 Treatment Regimen or Children or Adolescent With Mature B-cell NHL or B-AL in China Recruiting NCT02405676 Phase 2, Phase 3 Prednisone,Vincristine, Cyclophosphamide;Cyclophosphamide, Vincristine, Cytarabine, Doxorubincin, Prednisone;Ifosphamide, Etoposide, Methotrexate, Vincristine, Prednisone;Cyclophosphamide, Vindelsine, Cytarabine, Doxorubincin, Prednisone;Ifosphamide, Etoposide, Methotrexate, Vindelsine, Prednisone;Rituximab
13 Tisagenlecleucel Versus Standard of Care in Adult Patients With Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma: A Randomized, Open Label, Phase III Trial (BELINDA) Recruiting NCT03570892 Phase 3 Tisagenlecleucel after optional bridging and lymphodepleting chemotherapy;Platinum-based immunochemotherapy followed in responding patients with high dose chemotherapy and autologous hematopoietic stem cell transplant (HSCT)
14 Efficacy and Safety of Ibrutinib in Patients With Chronic Lymphocytic Leukemia and Other Indolent B-cell Lymphomas Who Are Chronic Hepatitis B Virus Carriers or Occult Hepatitis B Virus Carriers Recruiting NCT02991638 Phase 3 Ibrutinib
15 B-NHL 2013 - Treatment Protocol of the NHL-BFM and the NOPHO Study Groups for Mature Aggressive B-cell Lymphoma and Leukemia in Children and Adolescents Recruiting NCT03206671 Phase 3 Rituximab window;Additional doses of Rituximab;Cyclophosphamide;Cytarabine;Dexamethasone;Doxorubicin hydrochloride;Vindesine Sulfate;Etoposide;Ifosfamide;Methotrexate;Prednisolone;Vincristine
16 A Randomized, Open-label, Safety and Efficacy Study of Ibrutinib in Pediatric and Young Adult Patients With Relapsed or Refractory Mature B-cell Non-Hodgkin Lymphoma Recruiting NCT02703272 Phase 3 Ibrutinib;Rituximab;Ifosfamide;Carboplatin;Etoposide;Vincristine;Idarubicin;Dexamethasone
17 A Global Randomized Multicenter Phase 3 Trial of JCAR017 Compared to Standard of Care in Adult Subjects With High-risk, Second-line, Transplant-eligible Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphomas (TRANSFORM). Recruiting NCT03575351 Phase 3 Standard of Care
18 A Phase 3B Randomized Study of Lenalidomide (CC-5013) Plus Rituximab Maintenance Therapy Followed by Lenalidomide Single-Agent Maintenance Versus Rituximab in Subjects With Relapsed/Refractory Follicular, Marginal Zone, or Mantle Cell Lymphoma Recruiting NCT01996865 Phase 3 Lenalidomide;Rituximab
19 Mature B-Cell Lymphoma And Leukemia Study III Recruiting NCT01046825 Phase 2, Phase 3 COPAD;COP, COPD M3, CYM;COP, COPADM8, CYVE
20 A Prospective, Randomized, Open-label, Multi-center Study of Efficacy of Palliative Low-Dose Involved-Field Radiation Therapy for Recurrent Advanced Follicular Lymphoma: Wuhan University Cancer Center -NHL02 Trial Recruiting NCT02438501 Phase 3
21 Intergroup Trial for Children or Adolescents With B-Cell Non Hodgkin Lymphoma or B-Acute Leukemia: Evaluation of Rituximab Efficacy and Safety in High Risk Patients - Phase III Trial Active, not recruiting NCT01516580 Phase 3 Vincristine, cyclophosphamide, methotrexate, doxorubicin, cytarabine, ara-C;Rituximab, Vincristine, cyclophosphamide, methotrexate, doxorubicin, cytarabine, ara-C
22 A Randomised, Open Label, Multi-centre, Phase III Study to Investigate the Efficacy of Bendamustine Compared to Treatment of Physician's Choice in the Treatment of Subjects With Indolent Non-Hodgkin's Lymphoma (NHL) Refractory to Rituximab Terminated NCT01289223 Phase 3 Bendamustine IV
23 Phase III Randomized, Open Label Study of Single Agent Ofatumumab Vs. Single Agent Rituximab in Indolent B-Cell Non Hodgkin Lymphoma Relapsed After Rituximab-Containing Therapy Terminated NCT01200589 Phase 3
24 SPINOZA / שפינוזה. Study With Preparatory INduction Of Zevalin in Aggressive Lymphoma. A Randomized Phase 3 Study of BEAM Versus 90Yttrium Ibritumomab Tiuxetan (Zevalin) / BEAM in Patients Requiring ASCT for Relapsed DLBCL Terminated NCT02366663 Phase 3 Carmustine;Etoposide;Cytarabine;Melphalan
25 A Randomized, Open Label Study of Ofatumumab and Bendamustine Combination Therapy Compared With Bendamustine Monotherapy in Indolent B-cell Non-Hodgkin's Lymphoma Unresponsive to Rituximab or a Rituximab-Containing Regimen During or Within Six Months of Treatment Terminated NCT01077518 Phase 3 Ofatumumab (Arm A);Bendamustine infusion (Arm B);Bendamustine infusions (Arm A)
26 Study of Safety, Efficacy and Pharmacokinetics of CT-1530 in Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, and Waldenstrom's Macroglobulinemia Unknown status NCT02981745 Phase 1, Phase 2 CT-1530
27 Phase II Study for Treatment of Patients With Relapsed or Primary Refractory Aggressive B- Cell NHL and Anthracycline Chemotherapy Pretreatment, Who Received or Did Not Qualify for Autologous Stem Cell Transplantation. Unknown status NCT00385125 Phase 2 Bendamustine;Rituximab
28 Clinical Research of Gene Therapy for Refractory B-Cell Non-Hodgkin Lymphoma Using Autologous T Cells Expressing a Chimeric Antigen Receptor Specific to the CD19 Antigen Unknown status NCT02134262 Phase 1, Phase 2 Cyclophosphamide or Bendamustine
29 Diffuse Large B Cell Non-Hodgkin's Lymphoma in the Vulnerable/Frail Elderly. A Multicentric Randomized Phase II Trial With Emphasis on Geriatric Assessment and Quality of Life Unknown status NCT00911183 Phase 2 cyclophosphamide;liposome-encapsulated doxorubicin citrate;prednisone;vincristine sulfate
30 Intergroup Trial for Children or Adolescents With B-Cell NHL or B-AL: Evaluation of Rituximab Efficacy and Safety in High Risk Patients - Phase II Trial of DA-EPOCH-Rituximab in PMLBL Unknown status NCT01516567 Phase 2 Etoposide, Doxorubicin, Vincristine, Cyclophosphamide, Rituximab
31 A Phase II Single Arm Study of the Use of CODOX-M/IVAC With Rituximab (R-CODOX-M/IVAC) in the Treatment of Patients With Diffuse Large B-Cell Lymphoma (International Prognostic Index High or High-Intermediate Risk) Unknown status NCT00974792 Phase 2 cyclophosphamide;cytarabine;doxorubicin hydrochloride;etoposide phosphate;ifosfamide;leucovorin calcium;methotrexate;vincristine sulfate
32 A Phase I/II Study of Immunotherapy With hLL1-DOX in Patients With Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL) Unknown status NCT01585688 Phase 1, Phase 2 hLL1-DOX (IMMU-115)
33 Pilot Study of Autologous T Lymphocytes With Antibody-Dependent Cell Cytotoxicity in Patients With CD20-Positive B-Cell Malignancies Unknown status NCT02315118 Phase 1, Phase 2 T-cell therapy + Rituximab + IL-2
34 Phase II Dose Study of Doxil in a Dose Dense, 14 Day CDOP/Rituximab Regimen for Patients With Diffuse Large B-Cell NHL > 60 Years or With Compromised Cardiac Status Unknown status NCT00333008 Phase 2 Doxil;Cyclophosphamide;Vincristine;Prednisone;Rituximab;Pegfilgrastim
35 An Open-Label Extension Study of De-immunized DI-Leu16-IL2 Immunocytokine Administered in Patients With B-cell Non-Hodgkin Lymphoma (NHL) Completed NCT02151903 Phase 1, Phase 2 DI-Leu16-IL2
36 A Phase II Multicenter Study of ONTAK in Patients With Relapsed or Refractory, B-Cell Non-Hodgkins Lymphoma. Completed NCT00211276 Phase 2 ONTAK (denileukin diftitox)
37 A Phase II Trial of Oxaliplatin, Cytosine Arabinoside, Dexamethasone With Rituxan (ROAD) in Patients With Relapsed CD20+ B-Cell Non-Hodgkins Lymphoma Completed NCT00166439 Phase 2 Oxaliplatin, Cytosine Arabinoside, Dexamethasone With Rituxan (ROAD)
38 A Phase 1/2 Study of CAT-8015 in Adult Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia Completed NCT01030536 Phase 1, Phase 2 CAT-8015 20 mcg/kg;CAT-8015 30 mcg/kg;CAT-8015 40 mcg/kg;CAT-8015 50 mcg/kg;CAT-8015 60 mcg/kg
39 A Phase II Study of G3139 (Bcl-2 Antisense) And Rituximab in Patients With Recurrent B-cell Non-Hodgkinâs Lymphomas Completed NCT00054639 Phase 2
40 A Phase I/II Study of De-immunized DI-Leu16-IL2 Immunocytokine Administered Subcutaneously in Patients With B-cell Non-Hodgkin Lymphoma (NHL) Completed NCT01874288 Phase 1, Phase 2 0.5 mg/m2 DI-Leu16-IL2;1.0 mg/m2 DI-Leu16-IL2;2.0 mg/m2 DI-Leu16-IL2;4.0 mg/m2 DI-Leu16-IL2;6.0 mg/m2 DI-Leu16-IL2;8.0 mg/m2 DI-Leu16-IL2;10.0 mg/m2 DI-Leu16-IL2;50mg/m2 Rituximab
41 A Phase 1/2 Dose Escalation and Cohort Expansion Study of the Safety and Tolerability of Urelumab Administered in Combination With Nivolumab in Advanced/Metastatic Solid Tumors and B-cell Non-Hodgkins Lymphoma Completed NCT02253992 Phase 1, Phase 2
42 A Phase II Study of Velcade and Temsirolimus for Relapsed or Refractory B-cell Non-Hodgkin Lymphoma Completed NCT01281917 Phase 2 Velcade;Temsirolimus
43 A Phase II Randomized Study of Lenalidomide or Lenalidomide and Rituximab as Maintenance Therapy Following Standard Chemotherapy for Patients With High/High-intermediate Risk Diffuse Large B-Cell Lymphoma Completed NCT00765245 Phase 2 Lenalidomide;Lenalidomide;Rituximab
44 Phase II Study of Vorinostat (SAHA), Cladribine, and Rituximab (SCR) in Mantle Cell Lymphoma, Chronic Lymphocytic Leukemia, and Relapsed B Cell Non-Hodgkin Lymphoma Completed NCT00764517 Phase 2 Cladribine;Vorinostat
45 Bortezomib Plus Rituximab for EBV + Post Transplant Lymphoproliferative Disease (PTLD) Completed NCT01058239 Phase 2 bortezomib;rituximab
46 Randomized Phase II Study About the Application of Pegfilgrastim (Neulasta) at Day 2 or Day 4 Within the Treatment in Patients With Aggressive Non-Hodgkin's Lymphoma Aged 61 to 80 Years With 6 or 8 Cycles of Chemotherapy With CHOP (Cyclophosphamide, Doxorubicin, Vincristine and Prednisone) at 14-day Intervals (CHOP-14), Both With or Without the Monoclonal Anti-CD20 Antibody Rituximab Completed NCT00726700 Phase 2 cyclophosphamide;doxorubicin hydrochloride;prednisone;vincristine sulfate
47 A Pilot Study of Recombinant Humanized Anti- Cluster of Differentiation Antigen 20 (Anti-CD20) Antibody (Rituximab) in Patients With Moderate Aplastic Anemia, Pure Red Cell Aplasia, or Diamond Blackfan Anemia Completed NCT00229619 Phase 2 Rituximab
48 A Phase I Study of Immunotherapy With hA20 Administered Once Weekly for 4 Consecutive Weeks in Patients With CD20+ Non-Hodgkin's Lymphoma Completed NCT00285428 Phase 1, Phase 2 hA20-humanized anti-CD20 antibody
49 Phase I/II Radioimmunotherapy of Non-Hodgkin's Lymphoma With Radiolabeled Humanized Immuno-LL2: Treatment With 90Y-hLL2 IgG Completed NCT00061425 Phase 1, Phase 2 radiolabeled epratuzumab
50 A Phase II, Single-Arm, Open-Label Study of the Safety, Pharmacokinetics, and Efficacy of Multiple Doses of PRO95780 Administered Intravenously in Combination With Rituximab in Patients With Follicular, CD20-Positive B-Cell Non-Hodgkin's Lymphoma That Has Progressed Following Previous Rituximab Therapy Completed NCT00517049 Phase 2 PRO95780;rituximab

Search NIH Clinical Center for B-Cell Non-Hodgkin Lymphoma

Sources

Genetic Tests for B-Cell Non-Hodgkin Lymphoma

About this section

Genetic tests related to B-Cell Non-Hodgkin Lymphoma:

# Genetic test Affiliating Genes
1 B-Cell Non-Hodgkin Lymphoma 29
Sources

Anatomical Context for B-Cell Non-Hodgkin Lymphoma

About this section

MalaCards organs/tissues related to B-Cell Non-Hodgkin Lymphoma:

41
B Cells, T Cells, Bone, Nk Cells, Bone Marrow, Liver, Breast
Sources

Publications for B-Cell Non-Hodgkin Lymphoma

About this section

Articles related to B-Cell Non-Hodgkin Lymphoma:

(show top 50) (show all 1195)
# Title Authors PMID Year
1
Clustering of missense mutations in the ataxia-telangiectasia gene in a sporadic T-cell leukaemia. 71
9288106 1997
2
Pediatric mature B-cell NHL, early referral and supportive care problems in a developing country. 38
30149780 2019
3
Outcome of relapse in children and adolescents with B-cell non-Hodgkin lymphoma and mature acute leukemia: A report from the French LMB study. 38
31207026 2019
4
Beneficial effect of consolidative radiotherapy for patients with lymphoma and skeletal involvement. 38
31374054 2019
5
Burkitt lymphoma presenting with fever of unknown origin and isolated hypoglossal nerve palsy. 38
31425376 2019
6
Intussusception in children: lessons learned from intestinal lymphoma as a rare lead-point. 38
31139892 2019
7
Front-Line Treatment of High Grade B Cell Non-Hodgkin Lymphoma. 38
31254155 2019
8
CD19 CAR T cells following autologous transplantation in poor-risk relapsed and refractory B-cell non-Hodgkin lymphoma. 38
31262783 2019
9
Chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids (CLIPPERS) associated with or without lymphoma: Comparison of clinical features and risk factors suggestive of underlying lymphomas. 38
31088767 2019
10
Recent advances and future directions in mantle cell lymphoma research: report of the 2018 mantle cell lymphoma consortium workshop. 38
30696305 2019
11
Rituximab and reduced-intensity chemotherapy in children and adolescents with mature B-cell lymphoma: interim results for 231 patients enrolled in the second Russian-Belorussian multicentre study B-NHL-2010M. 38
31069789 2019
12
Prognostic Impact of Natural Killer Cell Count in Follicular Lymphoma and Diffuse Large B-cell Lymphoma Patients Treated with Immunochemotherapy. 38
31053601 2019
13
Metabolic tumor burden on baseline 18F-FDG PET/CT improves risk stratification in pediatric patients with mature B-cell lymphoma. 38
31187163 2019
14
Late Health Outcomes After Contemporary Lymphome Malin de Burkitt Therapy for Mature B-Cell Non-Hodgkin Lymphoma: A Report From the Childhood Cancer Survivor Study. 38
31283408 2019
15
Treatment of aggressive B-cell non-Hodgkin lymphoma beyond frontline therapy in patients not eligible for stem cell transplantation: a structured review. 38
30702000 2019
16
Combined rituximab, bendamustine, and dexamethasone chemotherapy for relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma: a multicenter phase II study. 38
31127456 2019
17
Daratumumab displays in vitro and in vivo anti-tumor activity in models of B cell non-Hodgkin lymphoma and improves responses to standard chemo-immunotherapy regimens. 38
31296574 2019
18
Early evaluation of tumor response to 90Y-ibritumomab radioimmunotherapy in relapsed/refractory B cell non-Hodgkin lymphoma: what is the optimal timing for FDG-PET/CT? 38
30899979 2019
19
Prediction of delayed platelet engraftment after autologous stem cell transplantation for B-cell non-Hodgkin lymphoma. 38
31318305 2019
20
Pregnancy-related factors and risk of B-cell non-Hodgkin lymphoma among women in Los Angeles. 38
30488431 2019
21
Remission of an HHV8-related extracavitary primary effusion lymphoma in an HIV-positive patient during antiretroviral treatment containing dolutegravir. 38
31351487 2019
22
Atypical Presentation of Small Lymphocytic Lymphoma with Pericardial Effusion. 38
31363076 2019
23
Differentiation of single lymphoma primary cells and normal B-cells based on their adhesion to mesenchymal stromal cells in optical tweezers. 38
31285461 2019
24
Hepatitis C virus infection and non-hepatocellular malignancies in the DAA era: A systematic review and meta-analysis. 38
30983083 2019
25
Early Progression As a Predictor of Survival in Marginal Zone Lymphomas: An Analysis from the FIL-NF10 Study. 38
31292118 2019
26
Chimeric antigen receptor T-cell therapy for the treatment of aggressive B-cell non-Hodgkin lymphomas: efficacy, toxicity, and comparative chimeric antigen receptor products. 38
31342797 2019
27
Polatuzumab vedotin in combination with immunochemotherapy in patients with previously untreated diffuse large B-cell lymphoma: an open-label, non-randomised, phase 1b-2 study. 38
31101489 2019
28
Tisagenlecleucel CAR-T Cell Therapy in Secondary CNS Lymphoma. 38
31320380 2019
29
The HDAC6-selective inhibitor is effective against non-Hodgkin lymphoma and synergizes with ibrutinib in follicular lymphoma. 38
30693983 2019
30
MicroRNA profiles in B-cell non-Hodgkin lymphoma. 38
31263393 2019
31
Single arm phase II trial assessing the safety, compliance with and activity of Bezafibrate and medroxyProgesterone acetate (BaP) therapy against myeloid and lymphoid cancers. 38
31011660 2019
32
Population pharmacokinetics of inotuzumab ozogamicin in relapsed/refractory acute lymphoblastic leukemia and non-Hodgkin lymphoma. 38
30859374 2019
33
Phase 1-2 study of vorinostat (SAHA), cladribine and rituximab (SCR) in relapsed B-cell non-Hodgkin lymphoma and previously untreated mantle cell lymphoma. 38
31177537 2019
34
Advances in cellular and humoral immunotherapy - implications for the treatment of poor risk childhood, adolescent, and young adult B-cell non-Hodgkin lymphoma. 38
30613939 2019
35
Temozolomide-induced aplastic anaemia and incidental low-grade B-cell non-Hodgkin lymphoma in a geriatric patient with glioblastoma multiforme. 38
31256047 2019
36
Immune profiling in diffuse large B-cell lymphoma and mantle cell lymphoma patients treated with autologous hematopoietic cell transplant. 38
31227776 2019
37
MiRNA-26b downregulation in peripheral blood mononuclear cells of patients with hepatitis c associated lymphomas is restored by successful interferon-free antiviral therapy. 38
31180334 2019
38
Both chronic HBV infection and naturally acquired HBV immunity confer increased risks of B-cell non-Hodgkin lymphoma. 38
31113483 2019
39
Sporadic Burkitt's Lymphoma of the Hypopharynx: A Case Report. 38
31080393 2019
40
An update on Burkitt lymphoma: a review of pathogenesis and multimodality imaging assessment of disease presentation, treatment response, and recurrence. 38
31115699 2019
41
Phase I study of tirabrutinib (ONO-4059/GS-4059) in patients with relapsed or refractory B-cell malignancies in Japan. 38
30815927 2019
42
Chimeric antigen receptor modified T cell therapy in B cell non-Hodgkin lymphomas. 38
30652353 2019
43
Safety and feasibility of chimeric antigen receptor T cell therapy after allogeneic hematopoietic cell transplantation in relapsed/ refractory B cell non-Hodgkin lymphoma. 38
31114023 2019
44
Long-term results with the adapted LMB 96 protocol in children with B-cell non Hodgkin lymphoma treated in Iraq: comparison in two subsequent cohorts of patients. 38
30997873 2019
45
Phase 2 Study of Daratumumab in Relapsed/Refractory Mantle-Cell Lymphoma, Diffuse Large B-Cell Lymphoma, and Follicular Lymphoma. 38
30795996 2019
46
[Unmittelbare Remission eines mit großzelligem B-Non-Hodgkin-Lymphom befallenen inguinalen Lymphknotens unter alleiniger homöopathischer Behandlung mit Conium: Wann ist eine alleinige adjuvant-homöopathische Tumortherapie zulässig und sinnvoll?] 38
31104055 2019
47
Incidental lymphoma in lymph node dissection for carcinoma in the abdominopelvic cavity: a single-institution experience. 38
31044268 2019
48
Review of Bruton tyrosine kinase inhibitors for the treatment of relapsed or refractory mantle cell lymphoma. 38
31043832 2019
49
Successful use of cytarabine and bendamustine in a patient with mantle cell lymphoma and acute renal failure using intermittent hemodialysis: A case report. 38
29385883 2019
50
Safety and tolerability of conditioning chemotherapy followed by CD19-targeted CAR T cells for relapsed/refractory CLL. 38
30938714 2019
Sources

Variations for B-Cell Non-Hodgkin Lymphoma

About this section

ClinVar genetic disease variations for B-Cell Non-Hodgkin Lymphoma:

6
# Gene Variation Type Significance SNP ID GRCh37 Pos GRCh38 Pos
1 ATM NM_000051.3(ATM): c.3118A> G (p.Met1040Val) single nucleotide variant Benign/Likely benign rs3092857 11:108143299-108143299 11:108272572-108272572
Sources

Expression for B-Cell Non-Hodgkin Lymphoma

About this section
Search GEO for disease gene expression data for B-Cell Non-Hodgkin Lymphoma.
Sources

Pathways for B-Cell Non-Hodgkin Lymphoma

About this section

Pathways related to B-Cell Non-Hodgkin Lymphoma according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
NF-kappaB Signaling 4
11.95 NFKB2 LCP1 BCL6
2
B Cell Development Pathways 65
10.88 MS4A1 BCL6
3
DNA Damage Response (only ATM dependent) 1
10.86 NFKB2 BCL6 ATM
4
DNA damage_ATM/ATR regulation of G1/S checkpoint 22
10.6 NFKB2 ATM
Sources

GO Terms for B-Cell Non-Hodgkin Lymphoma

About this section

Biological processes related to B-Cell Non-Hodgkin Lymphoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 germinal center formation GO:0002467 8.62 NFKB2 BCL6
Sources

Sources for B-Cell Non-Hodgkin Lymphoma

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....